Adverse Business Developments Sample Clauses

Adverse Business Developments. No notice has been received by Seller or any Shareholder of any new or substantially expanded firm or individual engaged in a business directly competitive to Seller in its primary service area within six (6) months before the date hereof. Neither Seller nor any Shareholder has received, either orally or in writing, any notice specific to it of pending or threatened adverse action with respect to any Medicare, Medicaid, private insurance or third party payor reimbursement method, practice or allowance as to any business activity engaged in by Seller, nor has Seller or any Shareholder received, or been threatened with, any claim for refund specific to it in excess of $500.00 by a Medicare or Medicaid carrier, except as disclosed in the Schedule of Proceedings attached hereto as Schedule 13(q).
AutoNDA by SimpleDocs
Adverse Business Developments. Neither the Corporation nor any Stockholder has received, either orally or in writing, any notice of pending or threatened adverse action with respect to any Medicare, Medicaid, private insurance or third party payer reimbursement method, practice or allowance as to any business activity engaged by Corporation, nor has the Corporation or any Stockholder received nor been threatened with any claim for refund in excess of $500 by a Medicare or Medicaid carrier, except as disclosed in the Schedule of Adverse Business Developments attached hereto as EXHIBIT 6-Z.
Adverse Business Developments. No notice has been received by ----------------------------- the Seller of any new or substantially expanded firm or individual engaged in a business directly competitive to Seller in its primary service area within six (6) months prior to the date hereof. Nor has Seller received, either orally or in writing, any notice specific to Seller of pending or threatened adverse action with respect to any Medicare, Medicaid, private insurance or third party payor reimbursement method, practice or allowance as to any business activity engaged by Seller, nor has Seller received nor been threatened with any claim for refund specific to Seller in excess of $500.00 by a Medicare or Medicaid carrier, except as disclosed in the Schedule of Proceedings attached hereto as Exhibit "Q," which may have a material adverse effect on Seller.
Adverse Business Developments. Neither the Seller nor any stockholder, director, officer or employee of Seller has received, either orally or in writing, any notice of pending or threatened adverse action with respect to any Medicare, Medicaid, private insurance or third party payer reimbursement method, practice or allowance as to any business activity engaged by Seller, nor has the Seller or any stockholder, director, officer or employee of Seller received nor been threatened with any claim for refund in excess of $500 by a Medicare or Medicaid carrier, except as disclosed in the Schedule of Adverse Business Developments attached hereto as EXHIBIT 7-X.
Adverse Business Developments. No notice has been received by the Company, the Subsidiary, any Guarantor or Shareholder of any new or substantially expanded firm or individual engaged in a business directly competitive to the Company or the Subsidiary in its primary service area within six (6) months before the date hereof that the Company, the Subsidiary, any Guarantor or Subsidiary reasonably believes will have a material adverse effect on the Business. None of the Company, the Subsidiary, the Guarantors and Shareholders has received, either orally or in writing, any notice specific to it of pending or threatened adverse action with respect to any Medicare, Medicaid, private insurance or third party payor reimbursement method, practice or allowance as to any business activity engaged in by the Company or the Subsidiary, nor has the Company, the Subsidiary, any Guarantor or any Shareholder received, or been threatened with, any claim for refund specific to it in excess of $750 by a Medicare or Medicaid carrier, except as disclosed in the Schedule of Proceedings attached hereto as Schedule 9.17.
Adverse Business Developments. No notice has been received by the Company or any Shareholder of any new or substantially expanded firm or individual engaged in a business directly competitive to the Company in its primary service area within six (6) months before the date hereof that the Company, the Subsidiary, any Guarantor or Subsidiary reasonably believes will have a material adverse effect on the Business. None of the Company and Shareholders has received, either orally or in writing, any notice specific to it of pending or threatened adverse action with respect to any Medicare, Medicaid, private insurance or third party payor reimbursement method, practice or allowance as to any business activity engaged in by the Company, nor has the Company or any Shareholder received, or been threatened with, any claim for refund specific to it in excess of $750 by a Medicare or Medicaid carrier, except as disclosed in the Schedule of Proceedings attached hereto as Schedule 9.17.
Adverse Business Developments. No notice has been received by Seller ----------------------------- of any new or substantially expanded firm or individual engaged in a business directly competitive to Seller in its primary service area within six (6) months prior to the date hereof. Nor has Seller received, either orally or in writing, any notice specific to Seller of pending or threatened adverse action with respect to any Medicare, Medicaid, private insurance or third party payor reimbursement method, practice or allowance as to any business activity engaged by Seller, nor has Seller received nor been threatened with any material claim for refund specific to Seller by a Medicare or Medicaid carrier.
AutoNDA by SimpleDocs

Related to Adverse Business Developments

  • Business Development Provide advice and assistance in business growth and development of Party B. 业务发展。对乙方的业务发展提供建议和协助。

  • Business Development Company Buyer is a business development company as defined in Section 202(a)(22) of the Investment Advisors Act of 1940.

  • Status as Business Development Company The Borrower is an “investment company” that has elected to be regulated as a “business development company” within the meaning of the Investment Company Act and qualifies as a RIC.

  • Business Development Company Status The Company, during a period of at least 12 months from the Closing Time, will use its commercially reasonable efforts to maintain its status as a business development company; provided, however, the Company may cease to be, or withdraw its election as, a business development company, with the approval of the board of directors and a vote of stockholders as required by Section 58 of the 1940 Act or any successor provision.

  • Clinical Development (a) Stellartech shall design, develop and construct a Clinical Unit for each of the Thermage Disposable Device and the Thermage Generator, and any required component or subassembly thereof and shall deliver such Clinical Units to Thermage in accordance with the Development Program; (b) Stellartech shall deliver to Thermage such other Deliverables as are contemplated by the Development Program in accordance with the Development Program; and (c) as requested by Thermage and automatically at the conclusion of the Development Program, Stellartech, so long as Thermage is not in breach of its material obligation hereunder, shall deliver in writing to Thermage any and all data and information held by or in the control of Stellartech which is necessary or useful to obtain regulatory approval of the Products in the United States or any foreign country.

  • Adverse Developments Promptly after the Lessee acquires knowledge thereof, written notice of:

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Subsequent Developments After the date of this Contract and until the Closing Date, Seller shall use best efforts to keep Buyer fully informed of all subsequent developments of which Seller has knowledge (“Subsequent Developments”) which would cause any of Seller’s representations or warranties contained in this Contract to be no longer accurate in any material respect.

  • Regulatory Affairs Each Party shall advise the other Party of any regulatory action of which it is aware which would affect the Product in any country of the Territory.

  • Joint Development All inventions, know-how, trade secrets, data or information which result from joint development by the Parties hereto shall be jointly owned by the Parties. The Parties hereby agree to cooperate in good faith in the filing of any and all patent applications in all jurisdictions.

Time is Money Join Law Insider Premium to draft better contracts faster.